We continue to invest in our key growth initiatives and capabilities that support a long-term strategy, while being disciplined with our near-term expense management.

Feb 19, 2026 / receipt

We continue to invest in our key growth initiatives and capabilities that support a long-term strategy, while being disciplined with our near-term expense management.

Feb 19, 2026 / receipt, needs a key / Payman Kales, CEO | earnings call 2026-02-19 | transcript 7016c957-24ec-4f84-b2fc-172cafecbd96 | chars 3473-3639 | segment 3

Travel and entertainment 1,229 1,981 (752) (38.0) Bank fees and charges 1,479 1,745 (266) (15.2) All other SG&A 5,195 4,591 604 13.2 Total SG&A expense $ 116,410 $ 104,083 $ 12,327 11.8 __________ (a) Professional fees for the second quarter and first six months of 2026 were impacted by legal and advisory fees related to a stockholder activist matter and defense of a securities class action lawsuit.

filing / Aug 4, 2026 / receipt

Gross margin declined in the second quarter and first six months of 2026 compared to the same prior year period due to the negative impact of lower fixed cost absorption, partly offset by on-going cost reduction initiatives.

filing / Aug 4, 2026 / receipt

Restructuring charges (a) $ 2,448 $ 1,301 $ 1,147 88.2 % Acquisition and integration costs (b) 1,615 6,749 (5,134) (76.1) Other general expenses (c) 8,146 6 8,140 NM Total restructuring and other charges $ 12,209 $ 8,056 $ 4,153 51.6 __________ (a) Restructuring charges for the second quarter and first six months of 2026 and 2025 primarily consist of costs associated with our strategic reorganization

filing / Aug 4, 2026 / receipt

risks from our international operations; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and our business being indirectly subject to healthcare industry cost containment measures and third-party coverage and reimbursement policies that could result in reduced sales of our products; and

filing / Aug 4, 2026 / receipt

We incur costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative.

filing / Aug 4, 2026 / receipt

Travel and entertainment 437 1,175 (738) (62.8) Bank fees and charges 831 832 (1) (0.1) All other SG&A 2,928 2,495 433 17.4 Total SG&A expense $ 58,711 $ 51,160 $ 7,551 14.8 __________ (a) Compensation and benefits increased primarily due to annual merit increases, acquisitions, leadership transitions, and the execution of our enterprise resource planning system implementation.

filing / Apr 30, 2026 / receipt

Gross margin declined in the first quarter of 2026, compared to the same prior year period due to the negative impact of lower fixed cost absorption, partly offset by on-going cost reduction initiatives.

filing / Apr 30, 2026 / receipt

Restructuring charges (a) $ 607 $ 664 $ (57) (8.6) % Acquisition and integration costs (b) 1,442 4,742 (3,300) (69.6) Other general expenses (c) 723 (1) 724 NM Total restructuring and other charges $ 2,772 $ 5,405 $ (2,633) (48.7) __________ (a) Restructuring charges for the first three months of 2026 and 2025 primarily consist of costs associated with our strategic reorganization and alignment and ma

filing / Apr 30, 2026 / receipt

risks from our international operations; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and our business being indirectly subject to healthcare industry cost containment measures and third-party coverage and reimbursement policies that could result in reduced sales of our products; and

filing / Apr 30, 2026 / receipt

We incur costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative.

filing / Apr 30, 2026 / receipt